Cargando…
Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report
BACKGROUND: The purpose of pharmacovigilance (drug safety) is collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. It is meant to identify, characterize, prevent, or minimize actual or potential risks relating to medicinal products. To preven...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266149/ https://www.ncbi.nlm.nih.gov/pubmed/28079787 http://dx.doi.org/10.1097/MD.0000000000005075 |
_version_ | 1782500415588270080 |
---|---|
author | Schmouchkovitch, Arthur Herry, Héloïse Thuillier, Philippe Kerlan, Véronique Fleuret, Camille Le Toux, Guy Boisramé, Sylvie |
author_facet | Schmouchkovitch, Arthur Herry, Héloïse Thuillier, Philippe Kerlan, Véronique Fleuret, Camille Le Toux, Guy Boisramé, Sylvie |
author_sort | Schmouchkovitch, Arthur |
collection | PubMed |
description | BACKGROUND: The purpose of pharmacovigilance (drug safety) is collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. It is meant to identify, characterize, prevent, or minimize actual or potential risks relating to medicinal products. To prevent these adverse effects and improve our practice, health professionals have a duty to report side effects to assess this risk and evaluate the benefit/risk requirements. Mitotane (Lysodren) is used for treating adrenocortical carcinoma. Currently, no side effects concerning oral and genital mucosa have been reported. CASE SUMMARY: This case report is about a 50 years old woman. Six months after the initiation on mitotane treatment, she developed erosive lesions located on the oral and vaginal mucosa. These drug reactions were diagnosed as erosive lichen planus by the biopsy. This lichenoid lesions were resistant to the usual treatments, mitotane being at the time not replaceable. CONCLUSION: This case describes an unreported adverse effect of mitotane, it is – to our knowledge – the 1st description of erosive lichenoid drug reaction due to Mitotane. |
format | Online Article Text |
id | pubmed-5266149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-52661492017-02-07 Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report Schmouchkovitch, Arthur Herry, Héloïse Thuillier, Philippe Kerlan, Véronique Fleuret, Camille Le Toux, Guy Boisramé, Sylvie Medicine (Baltimore) 5900 BACKGROUND: The purpose of pharmacovigilance (drug safety) is collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. It is meant to identify, characterize, prevent, or minimize actual or potential risks relating to medicinal products. To prevent these adverse effects and improve our practice, health professionals have a duty to report side effects to assess this risk and evaluate the benefit/risk requirements. Mitotane (Lysodren) is used for treating adrenocortical carcinoma. Currently, no side effects concerning oral and genital mucosa have been reported. CASE SUMMARY: This case report is about a 50 years old woman. Six months after the initiation on mitotane treatment, she developed erosive lesions located on the oral and vaginal mucosa. These drug reactions were diagnosed as erosive lichen planus by the biopsy. This lichenoid lesions were resistant to the usual treatments, mitotane being at the time not replaceable. CONCLUSION: This case describes an unreported adverse effect of mitotane, it is – to our knowledge – the 1st description of erosive lichenoid drug reaction due to Mitotane. Wolters Kluwer Health 2017-01-13 /pmc/articles/PMC5266149/ /pubmed/28079787 http://dx.doi.org/10.1097/MD.0000000000005075 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 5900 Schmouchkovitch, Arthur Herry, Héloïse Thuillier, Philippe Kerlan, Véronique Fleuret, Camille Le Toux, Guy Boisramé, Sylvie Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report |
title | Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report |
title_full | Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report |
title_fullStr | Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report |
title_full_unstemmed | Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report |
title_short | Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report |
title_sort | oral and vulvo-vaginal lichenoid reactions due to mitotane (lysodren): a case report |
topic | 5900 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266149/ https://www.ncbi.nlm.nih.gov/pubmed/28079787 http://dx.doi.org/10.1097/MD.0000000000005075 |
work_keys_str_mv | AT schmouchkovitcharthur oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport AT herryheloise oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport AT thuillierphilippe oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport AT kerlanveronique oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport AT fleuretcamille oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport AT letouxguy oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport AT boisramesylvie oralandvulvovaginallichenoidreactionsduetomitotanelysodrenacasereport |